Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Esophageal Neoplasms × Standard of Care × Clear all

Phase

Phase NA 5 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 7 Breast Neoplasms 7 Lung Neoplasms 5 Head and Neck Neoplasms 5 Neoplasms 4 Leukemia, Myeloid, Acute 4 Hematologic Neoplasms 3 Colorectal Neoplasms 3 Recurrence 2 Pulmonary Disease, Chronic Obstructive 2 Neoplasm Metastasis 2 Leukemia 2 Colonic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Xerostomia 1 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Teratoma 1 Stroke 1 Stomatitis 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Radiation Injuries 1 Prostatic Diseases 1

Interventions

Cisplatin 28 Fluorouracil 21 Paclitaxel 19 Radiotherapy 16 Docetaxel 10 Radiation 7 Esophagectomy 7 Neoadjuvant Therapy 6 Irinotecan 6 Carboplatin 6 Oxaliplatin 5 Leucovorin 5 Capecitabine 5 sintilimab 4 pembrolizumab 4 camrelizumab 4 TP protocol 4 Surgical Procedures, Operative 4 Drug Therapy 4 Chemotherapy, Adjuvant 4 Trastuzumab 3 Immunotherapy 3 Chemoradiotherapy 3 tislelizumab 2 nimotuzumab 2 S 1 (combination) 2 Radiotherapy, Adjuvant 2 Platinum Compounds 2 Nivolumab 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05865743 2025-03-05

PERSuaDER

Radboud University Medical Center

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡